Merck subsidiary awarded $2.5bn in patent case against Gilead

16-12-2016

Merck subsidiary awarded $2.5bn in patent case against Gilead

Gil C / Shutterstock.com

Idenix Pharmaceuticals, a subsidiary of Merck, has been awarded $2.5 billion in a patent battle against Gilead over Gilead's drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), treatments for hepatitis C. 


Gilead, Merck, Idenix, patent, Sovaldi, Harvoni

LSIPR